Imunon, Inc. Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31)
Imunon, Inc. (IMNN) reported Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) of $12.17 thousand for the 12-month period ending 2015-12-31, per its 10-K filed 2017-03-24.
Discontinued › Income Statement › Other Income
us-gaap:AvailableforsaleSecuritiesGrossUnrealizedGainLoss1 · last filed 2017-03-24
- Imunon, Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2015 was $12.17K, a 56.73% decline from fiscal 2014.
- Imunon, Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2014 was $28.13K, a 65.87% decline from fiscal 2013.
- Imunon, Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2013 was $82.44K, a 45.07% decline from fiscal 2012.
- Imunon, Inc. available-for-sale securities, gross unrealized gain (loss) (deprecated 2018-01-31) for fiscal 2012 was $150.09K.
| Period end | Available-for-sale Securities, Gross Unrealized Gain (Loss) (Deprecated 2018-01-31) 12 month |
|---|---|
| 2015-12-31 | $12.17K 10-K · filed 2017-03-24 |
| 2014-12-31 | $28.13K 10-K · filed 2016-03-30 |
| 2013-12-31 | $82.44K 10-K · filed 2016-03-30 |
| 2012-12-31 | $150.09K 10-K · filed 2015-03-12 |
| 2011-12-31 | -$258.33K 10-K · filed 2014-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |